It's been a rough start to 2025 for Merck (NYSE: MRK) shareholders following a less-than-stellar fourth-quarter earnings ...

A new clinical trial from Scripps Research hopes to make significant gains in the global fight against malaria by making a drug that has been around since the 1970s last longer. Working with a ...

Shares of Merck & Co. Inc. MRK rallied 2.08% to $89.50 Friday, on what proved to be an all-around rough trading session for ...

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But ...

Peter Guenter to retire as healthcare CEO, replaced by Danny Bar-Zohar; Matthias Heinzel steps down from life science unit.